Relationship between acetylation polymorphism and risk of atopic diseases

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 5, 1999, Pages 562-569

  Gawrońska Szklarz, Barbara ^a   Luszawska Kutrzeba, Teresa ^b   Czaja Bulsa, Grazyna ^b   Kurzawski, Grzegorz ^b  

^a Lab of Pharmacokin and T   (Poland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DNA;

ACETYLATOR PHENOTYPE; ADOLESCENT; ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; ATOPIC DERMATITIS; ATOPY; CHILD; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ACETYLATION; ADOLESCENT; ADULT; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; ASTHMA; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; MUTATION; POLAND; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RHINITIS, ALLERGIC, PERENNIAL;

EID: 0032940878     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70076-7     Document Type: Article

References (39)

1. 1. Cookson W, Hopkin J. Dominant inheritance of atopic immunoglobulin-E responsiveness. Lancet 1988;16:86-8.
2. 2. Sears MR, Burrows B, Heribson GP, Flannery EM, Holdaway MD. Atopy in childhood; III: relationship with pulmonary function and airway responsiveness. Clin Exp Allergy 1993;23:957-63.
3. 3. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CJ, et al. Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995;14:849-900.
4. 4. Hopkin JM. Genetics of atopy. Clin Exp Allergy 1989;19: 263-5.
5. 5. Cookson W. Atopy: a complex genetic disease. Ann Med 1994;26:351-3.
6. 6. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-41.
7. 7. Weber WW, Hein DW. N-Acetylation pharmacogenetics. Pharmacol Rev 1985;37:25-79.
8. 8. Maslinski C, Fogel A. Catabolism of histamine. In: Uväns B, editor. Handbook of experimental pharmacology: histamine and histamine antagonists. Berlin: Springer-Verlag; 1991:165-89.
9. 9. Endo Y. Elevation of histamine levels in rat and mouse tissue by deacetylation of administered N-acetylhistamine. Eur J Pharmacol 1979;60:299-305.
10. 10. Tabor H, Mehler AH, Stadtman ER. The enzymatic acetylation of amines. J Biol Chem 1953;204:127-38.
11. 11. Hickman D, Sim E. N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-14.
12. 12. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985;29:342-75.
13. 13. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993;3:45-50.
14. 14. Vatsis KP, Weber WW, Bell DA, Dupert JM, Evans DAP, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1991;5:1-17.
15. 15. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991;88:6333-7.
16. 16. Cascorbi J, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotype activity. Am J Hum Genet 1995;57:581-92.
17. 17. Pontes ZB, Vincent-Viry H, Gueguen MM, Galtean MM, Siest G. Acetylation phenotypes and biological variation in a French population. Eur J Clin Chem Clin Biochem 1993;31:59-68.
18. 18. Gawrońska-Szklarz B, Górnik W, Pawlik A, Kunicki P, Wójcicki J, Sitkiewicz, D, et al. N-Acetylation and hydroxylation polymorphism in type II diabetics with microvascular disturbances. Eur J Clin Pharmacol 1997;51:431-36.
19. 19. Evans DAP. N-Acetyltransferase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 95-178.
20. 20. Roots I, Drakoulis N, Brockmöller J. Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: Kalow W. editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992;815-41.
21. 21. Patkowski J, Malolepszy J, Milejski P, Orzechowska-Juzwenko K, Nittner-Marszalska M. Acetylation phenotype in the atopic allergy [in Polish]. Pol Tyg Lek 1987;42:870-3.
22. 22. Zielińska E, Niewiarowski W, Bodalski J, Stańczyk A, Bolanowski W, Rȩbowski G. Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin Pharmacol Ther 1997;62:635-42.
23. 23. Gustincich S, Manfioletti G, Del Sal G, Carninci P. A fast method for high-quality genomic DNA extraction from whole blood. Biotechniques 1991;11:298-301.
24. 24. Spurr NN, Gough AC, Chinegwundoh FJ. Polymorphisms in long-metabolizing enzymes as modifiers of cancer risk. Clin Chem 1995;12:1864-69.
25. 25. Haahtela T, Heiskala M, Suoniemi J. Allergic disorders and immediate skin test reactivity in Finnish adolescents. Allergy 1980;35:433-41.
26. 26. Williams UC. Atopic dermatitis: new information from epidemiological studies. Br J Hosp Med 1994;52:409-12.
27. 27. Weeke ER. Epidemiology of allergic diseases in children. Rhinol Suppl 1992;13:5-12.
28. 28. Marsh DG, Meyers DA, Bias WB. The epidemiology and genetics of atopic allergy. N Engl J Med 1981;305:1551-9.
29. 29. Orzechowska-Juzwenko K, Milejski P, Patkowski J, Nitter-Marszalska M, Malolepszy J. Acetylation phenotype in patients with allergic diseases and its clinical significance. Int J Clin Pharmacol Ther Toxicol 1990;10:420-5.
30. 30. Vatsis KP, Weber WW. Structural heterogeneity at Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993;301:71-6.
31. 31. Skrȩtkowicz J, Mazurowa A, Orszulak D. Acetylation phenotype in a group of population from the Łódź region [in Polish]. Pol Tyg Lek 1981;3:89-91.
32. 32. Mrozikiewicz PM, Cascorbi J, Brockmöller J, Roots I. Determination and allelic allocation of 7 nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 1996;59: 376-82.
33. 33. Bouchardy Ch, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S, et al. N-Acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998;8:291-8.
34. 34. Blumenthal MN, Mendel N, Yunis E. Immunogenetics of atopic diseases. J Allergy Clin Immunol 1980;65:403-5.
35. 35. Sutton BJ, Gould HJ. The human IgE network. Nature 1993;366:421-28.
36. 36. White MU, Slater JE, Kaliner MA. Histamine and asthma. Am Rev Respir Dis 1987;135:1165-76.
37. 37. Kaplan AP, Haak-Frenscho M, Fanci A, Dinarello C, Halbert E. A histamine releasing factor from activated human mononuclear cells. J Immunol 1985;135:2027-32.
38. 38. Bush RK, Busse W, Reed CE. Effects of experimental rhinovirus 16 infection on airway and leukocyte function in normal subjects. J Allergy Clin Immunol 1978;61:80-7.
39. 39. Patkowski J. Acetylation phenotype and immunological reactivity in bronchial asthma and in allergies to drugs [in Polish]. Wrocław, Poland: Medical University; 1989.